speaker-icon

Latest Posts

anavex_partex_partnership_Innoplexus

27

Jun 23

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to...
Read More
Kittu-Press-Release

9

Feb 23

AI supports targeted therapy recommendations fortumor diseases – BMBF funds joint research projectat University Medical Center Mainz with 2.53 millionEuros

The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More

WHITEPAPERS

EY-report-banner

Autoimmune
Index report

Autoimmune Index report provides you with a perspective on the new commercial and clinical opportunities by assessing their clinical innovation aspect. Innoplexus’ AI based CTP engine was leveraged to predict the success probability of clinical assets.
CTP-model-banner

Innoplexus’
CTP model

Innoplexus’ CTP model forecasts the outcome of clinical studies and may serve as an early indicator for future stock movements.
Gene-therapy-banner

Gene
Therapy

Gene therapy promises to hold the cure to a number of diseases which, until now, have been considered incurable. By replacing a faulty gene in a patient’s DNA or repairing a defective gene by gene editing, gene therapy can provide a one-time treatment option for diseases such as genetic blindness, muscular dystrophy, blood cancer. Read our recent whitepaper: Advancements in gene therapy – usage of AAV vectors here.
antigen-banner

Emergence of
chimeric antigen

Emergence of chimeric antigen receptor-t (CAR-T) cell therapies for cancer treatment